Steven J. Bernstein, MD

Articles by Steven J. Bernstein, MD

Moving From A to Z: Successful Implementation of a Statin Switch Program by a Large Physician Group

ByFangyan Z. Sy, PharmD,Hae Mi Choe, PharmD,Diane M. Kennedy, BS,Connie J. Standiford, MD,Dawn M. Parsons, RPh, MBA,Keith D. Bruhnsen, MSW,James G. Stevenson, PharmD,Steven J. Bernstein, MD

April 2nd 2009

This report shows that a successful, cost-effective statin switch program can be implemented by a large physician group via a centralized, collaborative process.

Frequency of Negative Coronary Arteriographic Findings in Patients with Chest Pain Is Related to Community Practice Patterns

ByPeter M. Farrehi, MD,Steven J. Bernstein, MD,Mark Rasak, DO,Samir A. Dabbous, MD,Robert J. Stomel, DO,Kim A. Eagle, MD,Melvyn Rubenfir

July 1st 2002

Steven J. Bernstein, MD

Articles by Steven J. Bernstein, MD

Moving From A to Z: Successful Implementation of a Statin Switch Program by a Large Physician Group

Frequency of Negative Coronary Arteriographic Findings in Patients with Chest Pain Is Related to Community Practice Patterns

Latest Updated Articles

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Steven J. Bernstein, MD

Articles by Steven J. Bernstein, MD

Moving From A to Z: Successful Implementation of a Statin Switch Program by a Large Physician Group

Frequency of Negative Coronary Arteriographic Findings in Patients with Chest Pain Is Related to Community Practice Patterns

Latest Updated Articles

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care